An observational study in Rectal Adenocarcinoma, Stage I Rectal Cancer AJCC v8 and Stage II Rectal Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Rectal Neoplasms by M.D. Anderson Cancer Center — 3 open to participants now, 10 under way, none of them phase 3. Rectal Neoplasms · M.D. Anderson Cancer Center.
Among the 27 studies in Rectal Neoplasms by M.D. Anderson Cancer Center, this one is the only one that started in 2014, is one of 5 observational ones, and was the 15th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →3 of the 27 studies in Rectal Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 2
First in 1997; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 430 is above the median of 161 across 499 observational studies indexed under Rectal Neoplasms.
Median enrollment 26 across the 22 interventional studies, 341 across the 5 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
3 of the studies in Rectal Neoplasms by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02874885M.D. Anderson Cancer CenterCirculating Tumor Cells in Patients With Locally Advanced Rectal Cancer | 2027-04-30 |
| NCT00648635M.D. Anderson Cancer CenterRelationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations | 2027-09-30 |
| NCT06569368M.D. Anderson Cancer CenterTrial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies in Rectal Neoplasms by M.D. Anderson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates quality of life and utilities following surgical treatment of stage I-IV rectal cancer. This study may help researches learn more about quality of life in patients who have or have had rectal cancer.
PRIMARY OBJECTIVE:
I. To assess post-treatment related health state utilities among patients with rectal cancer after treatment at 2 years.
SECONDARY OBJECTIVES:
I. To longitudinally compare the effects of treatment on quality of life and utilities among patients treated with or without (neo)adjuvant radiation therapy.
II. To characterize the impact of treatment on quality of life and utilities among patients with rectal cancer.
III. To assess changes in quality of life and utilities among patients treated for rectal cancer over time.
IV. To identify gaps in preoperative counseling for pelvic exenteration by eliciting in-depth insights into patient values, expectations, and lived experiences through qualitative interviews with patients who have undergone surgery for locally advanced or recurrent rectal cancer.
V. To identify themes, communication strategies, and informational content used during preoperative counseling for pelvic exenteration through qualitative interviews with providers.
OUTLINE:
Patients complete quality of life questionnaires over 20-30 minutes at baseline, 6 and 12 months after surgery, and 2, 3, 4, and 5 years after surgery.
Patient with stave I-IV rectal adenocarcinoma at the Colorectal Clinic at M D Anderson Cancer Center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients complete quality of life questionnaires over 20-30 minutes at baseline, 6 and 12 months after surgery, and 2, 3, 4, and 5 years after surgery.
Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Complete quality of life questionnaire
Also known as: Quality of Life Assessment
Complete quality of life questionnaire
Health state utilities
A health state utility is the degree of preference that individuals or society has for a particular health state or condition.
Time frame: At 24 months post-surgery
Started May 2014 (actual). Primary completion is estimated for May 2030, 192 months after the start.
Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 192 months is above that.
Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.